[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Bio‑Rad Laboratories (BIO) executive Sedat Evran (EVP, Global Supply Chain) reported routine equity vesting. On 10/20/2025, 1,044 restricted stock units converted into Class A common stock at $0 per the award terms, and 335 shares were withheld at $321.90 to cover taxes. Following these transactions, Evran beneficially owned 2,232.847 Class A shares.

The RSUs relate to a grant of 4,176 units made on 10/20/2023, vesting in four equal annual installments beginning on the first anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EVRAN SEDAT

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Supply Chain

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	10/20/2025	10/20/2025	M		1,044(1)	A	$0	2,567.847	D
Bio-Rad A Common Stock	10/20/2025	10/20/2025	F		335	D	$321.9	2,232.847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	10/20/2025	10/20/2025	M			1,044	(3)	(3)	Bio-Rad A Common Stock	1,044	$0	2,088	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Sedat Evran	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BIO’s executive report on Form 4?

A vesting of 1,044 RSUs into Class A common stock on 10/20/2025, and tax withholding of 335 shares at $321.90.

How many BIO shares does the reporting person own after the transactions?

Beneficial ownership is 2,232.847 Class A shares (direct).

What is the origin of the vested BIO RSUs?

They are part of a 4,176-unit grant made on 10/20/2023, vesting in four equal annual installments.

What do the Form 4 transaction codes M and F mean here for BIO?

M: RSUs converted into shares at $0. F: shares withheld (335) to satisfy taxes at $321.90.

What is the reporting person’s role at Bio‑Rad (BIO)?

The filer is an officer: EVP, Global Supply Chain.

Which class of BIO stock was involved?

Bio‑Rad Class A common stock.